We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

95 hedge funds and large institutions have $998M invested in G1 Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 18 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 18

35% more capital invested

Capital invested by funds: $741M → $998M (+$258M)

1% more funds holding

Funds holding: 94 → 95 (+1)

5% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 20

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
95
Holders Change
+1
Holders Change %
+1.06%
% of All Funds
2.17%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
21
Increased
44
Reduced
18
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$50.7M
2
State Street
State Street
Massachusetts
+$30.9M
3
Capital World Investors
Capital World Investors
California
+$23.1M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$19M
5
BlackRock
BlackRock
New York
+$17.5M

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$24.5M
2
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$10.2M
3
EA
Emerald Advisers
Pennsylvania
-$8.4M
4
GTC
Ghost Tree Capital
New York
-$5.56M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
Norges Bank
101
Norges Bank
Norway
– -$1.48M -40,000 Closed
PPA
102
Parametric Portfolio Associates
Washington
– -$1.42M -38,374 Closed
LCM
103
Laurion Capital Management
New York
– -$1.26M -34,016 Closed
Renaissance Technologies
104
Renaissance Technologies
New York
– -$1.19M -32,000 Closed
Ameriprise
105
Ameriprise
Minnesota
– -$1.14M -30,769 Closed
EGI
106
EAM Global Investors
California
– -$1.06M -28,713 Closed
Millennium Management
107
Millennium Management
New York
– -$659K -17,797 Closed
SSA
108
Schonfeld Strategic Advisors
New York
– -$442K -11,919 Closed
Citadel Advisors
109
Citadel Advisors
Florida
– -$308K -8,324 Closed
VF
110
Virtu Financial
New York
– -$289K -7,799 Closed
BCM
111
BlueCrest Capital Management
Jersey
– -$224K -6,042 Closed
TAM
112
Tiverton Asset Management
Delaware
– -$186K -5,000 Closed
CSS
113
Cubist Systematic Strategies
Connecticut
– -$104K -2,794 Closed
DZ Bank
114
DZ Bank
Germany
– -$83K -2,253 Closed
FPFS
115
First Personal Financial Services
North Carolina
– -$8K -218 Closed
1 2 3 4
5

GTHX Hedge Fund Activity: Q2 2018 in Review

95 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2018, worth a combined $998M — up 35% from $741M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new GTHX positions and 20 closed out — a net gain of 1 holder — while 44 added to existing stakes and 18 trimmed.

The largest buyer was Bank of New York Mellon, adding an estimated $50.7M. The largest seller was Boxer Capital, exiting entirely with an estimated $24.5M sold.

  • 95 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2018, up from 94 in Q1 2018.
  • Funds reported $998M of G1 Therapeutics, Inc. Common Stock stock for Q2 2018, up 35% quarter-over-quarter.
  • 21 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2018 and 20 closed out, a net change of +1 holder.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2018 was Bank of New York Mellon, an estimated $50.7M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2018 was Boxer Capital, an estimated $24.5M sold.

Based on aggregated 13F filings for Q2 2018.